Recce Pharmaceuticals

Corporate Governance

Why Invest

News and Media

Announcements

Titillium Web

Recce's Entitlement Offer is now live! Visit the page for instructions on how to participate

Recce Pharmaceuticals’ (RCE) phase I/II R327 topical burn wound clinical trial successfully treats bacterial infections in all patients to date

Clinicians report a visible reduction in bacterial infections within the first 24 hours of using R327, with the ability to treat multidrug-resistant pathogens

The results are grounds to commence a phase I/II diabetic foot infection trial, which will be the largest in Australia

RCE shares closed down 0.69 per cent, trading at 71.5 cents at market close

Recce Pharmaceuticals (RCE) has completed data analysis for its phase I/II topical clinical trial using R327 for the treatment of burn wounds.

The company has announced the successful treatment of bacterial infections in all patients to date.

During the trial, clinicians reported a visible reduction in bacterial infections within the first 24 hours of using R327 and noted broad-spectrum antibiotic activity against gram-positive and gram-negative pathogens.

These pathogens, which are multidrug-resistant and challenging to treat with standard antibiotics, have shown susceptibility to R327, which is more potent than conventional anti-infectives. Indications have demonstrated that if treatment is missed for one or two days, wounds can begin to deteriorate.

The drug has demonstrated an absence of adverse reactions and is deemed safe and well-tolerated.

RCE CEO James Graham said he was thankful to the West Australian Government for sponsoring the investigation, which has ultimately led to the commencement of a phase I/II diabetic foot infection trial, the largest to be conducted in Australia.

“The patient data received has paved the way to advance this new class of anti-infective as a topical application against deadly bacterial pathogens and a broad range of infectious diseases beyond,” he said.

To progress toward a stage two topical clinical trial for burn wounds using R327, Recce aims to target a larger patient population for comparison with the current standard of care.

RCE shares closed down 0.69 per cent, trading at 71.5 cents at market close.

Read the full article here: https://themarketherald.com.au/recce-pharmaceuticals-asxrce-concludes-stage-one-analysis-of-phase-i-ii-r327-topical-trial-for-burn-wounds-2023-08-21/

Recce Pharmaceuticals (ASX:RCE) concludes stage one analysis of phase I/II R327 topical trial for burn wounds